uk English news | uk, Latest News & Live Updates in English | English News (Latest English News) at Lokmattimes.com

London, Dec 24 British-Swedish drugmaker AstraZeneca has announced that its antibody drug 'Evusheld' is effective against the new vaccine evading Omicron variant of Covid-19.The finding is based on alive virus neutralisation data from University College Oxford, UK, and Washington University School of Medicine, US, which showed that Evusheld (tixagevimab co-packaged with cilgavimab) retains neutralisation activity against the Omicron SARS-CoV-2 variant (B.1.1.529), the company said in a statement.While the Omicron variant was not in circulation during the Evusheld clinical trials, the company added that it is continuing to collect further data to better understand the implications of this data in clinical practice. The findings from both studies were posted online on preprint server bioRxiv, and not peer-reviewed yet.In early December, the US Food and Drug Administration granted emergency use authorisation (EUA) to Evusheld an injectable monoclonal antibody cocktail of tixagevimab co-packaged with cilgavimab for Covid-19 among people with weakened immune systems. It is the first antibody treatment against Covid-19 that has won an EUA from the drug regulator.According to the researchers, the levels of neutralising potency are within the range of titres found in individuals who have been previously infected with and recovered naturally from Covid-19.The data were generated from laboratory testing using actual live virus isolated from individuals who contracted the Omicron variant of Covid-19 considered a 'gold standard' for antibody neutralisation studies.Evusheld is one of only two antibody therapies authorised for use that showed neutralising activity against Omicron and against all other variants of concern in these two studies."Consistent data across three independent studies now provide confidence that Evusheld a combination of two highly potent antibodies retains neutralising activity against the Omicron variant at a level that will continue to provide benefit to patients," said Mene Pangalos, Executive Vice-President, BioPharmaceuticals R&D, AstraZeneca."Evusheld is now available to help protect vulnerable populations, such as the immunocompromised, who are unable to mount an adequate response to vaccination and remain at high-risk of Covid-19," Pangalos added.Besides the US, Evusheld has also won approval from drug authorities in other countries, including France and Italy.Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

UkFOLLOW

Uk, Latest News

Goa detected its first case of COVID-19's Omicron variant on Monday. ...

The funeral of Desmond Mpilo Tutu, South African Anglican archbishop, human rights activist and Nobel Peace Prize winner will take place on January 1 in Cape Town, his foundation has announced. ...

US President Joe Biden and First Lady Jill Biden have expressed condolences over the death of Desmond Mpilo Tutu, South African Anglican archbishop, human rights activist and Nobel Peace Prize winner. ...

London, Dec 26 Ketamine therapy has a swift short-term effect on reducing symptoms of depression and suicidal thoughts, ... ...

Lokmat News Network Aurangabad, Dec 25: The National Institute of Virology (NIV- Pune) has released the Genome Sequencing report ... ...

London, Dec 25 People getting infected with Omicron are 50 per cent to 70 per cent less likely ... ...

London, Dec 24 While countries are racing to administer booster shots to protect against the Omicron variant of ... ...

London, Dec 24 British-Swedish drugmaker AstraZeneca has announced that its antibody drug 'Evusheld' is effective against the new ... ...